Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
View Patent ↗A description is given of a process for the preparation of a pharmaceutical composition of a macrolide antibiotic in essentially noncrystalline form, in which the macrolide antibiotic, a water-swellable polymer and a proton donor are blended in an extruder in the presence of water and forced through a die, the ratio by weight of the sum of macrolide antibiotic, water-swellable polymer and proton donor to water being at least 1:1. The macrolide antibiotic is preferably clarithromycin and the water-swellable polymer is preferably chosen from crosslinked polyvinylpyrrolidone, crosslinked sodium carboxymethylcellulose and crosslinked polyacrylic acid.
1. A process for the preparation of a pharmaceutical composition of a macrolide antibiotic in essentially noncrystalline form, comprising
mixing the macrolide antibiotic and a water-swellable polymer as a blend, wherein the mixing takes place in an extruder in the presence of water to obtain a mixture; and
forcing the mixture through a die,
wherein said water-swellable polymer is selected from crosslinked polyvinylpyrrolidone, crosslinked sodium carboxymethyl-cellulose, and crosslinked polyacrylic acid,
provided that when the water-swellable polymer does not comprise crosslinked polyacrylic acid, the blend further comprises a proton donor that is mixed with the macrolide antibiotic and the water-swellable polymer;
wherein the ratio by weight of the blend to water is at least 1:1.
2. The process as claimed in claim 1 , wherein the macrolide antibiotic is present at 50% to 80% by weight of the blend.
3. The process as claimed in claim 2 , wherein the macrolide antibiotic is present at 60% to 80% by weight of the blend.
4. The process as claimed in claim 1 , wherein the macrolide antibiotic is present in molecular disperse form in the composition obtained.
5. The process as claimed in claim 1 , wherein the macrolide antibiotic is present in amorphous form in the composition obtained.
6. The process as claimed in claim 1 , wherein the macrolide antibiotic is selected from clarithromycin, roxithromycin, erythromycin and azithromycin.
7. The process as claimed in claim 6 , wherein the macrolide antibiotic is clarithromycin.
8. The process as claimed in claim 1 , wherein the water-swellable polymer has a water absorption capacity of at least 3.5 g of water/g of polymer.
9. The process as claimed in claim 1 , wherein the proton donor is an organic acid.
10. The process as claimed in claim 9 , wherein the organic acid is lactic acid, glycolic acid or citric acid.
11. The process as claimed in claim 9 , wherein the organic acid is lactic acid.
12. The process as claimed in claim 1 , wherein the ratio by weight of the blend to water is from 1:1 to 2.7:1.
13. The process as claimed in claim 1 , wherein the water is added to the blend before the feeding of the blend to the extruder.
14. The process as claimed in claim 1 , wherein the water is added to the blend at least partially in a conveying zone of the extruder.
15. The process as claimed in claim 1 , wherein the mixture is extruded as a temperature in the range of between 40 and 80° C.
16. The process as claimed in claim 1 , in which the mixture is subjected to a vacuum before the die in order to at least partially remove the water.
17. The process as claimed in claim 1 , wherein the ratio by weight of the blend to water is from 1.5:1up to less than 1.9:1, and the mixture is extruded at a temperature of 40°C. or higher.
18. The process as claimed in claim 1 , wherein the extruder is a multi-screw extruder.
19. The process as claimed in claim 1 , wherein the ratio by weight of the blend to water is 1.9:1 or greater, and the mixture is extruded at a temperature of 50° C. or higher.